Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents

Antiviral Research

Volumn 77, Issue 2, 2008, Pages 157-162

  Hwu, Jih Ru ^a   Singha, Raghunath ^a   Hong, Shih Ching ^a   Chang, Yung Hsiung ^a   Das, Asish R ^a   Vliegen, Inge ^b   De Clercq, Erik ^b   Neyts, Johan ^b  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Anti HCV; Benzimidazole; Conjugate; Coumarin; N Glucosides

Indexed keywords

1 [(2'',3'',4'',6'' TETRA O ACETYL)GLUCOPYRANOS 1'' YL] 2 [(6' BROMOCOUMARIN 3' YL)METHYLENETHIO]BENZIMIDAZOLE; 2 [(6' BROMOCOUMARIN 3' YL)METHYLENETHIO] 5 FLUOROBENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; COUMARIN DERIVATIVE; GLUCOPYRANOSIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONJUGATE; CONTROLLED STUDY; COXSACKIE VIRUS B4; CYTOSTASIS; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MAMMALIAN ORTHOREOVIRUS; NONHUMAN; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; REPLICON; SINDBIS VIRUS; STRUCTURE ACTIVITY RELATION; TOROVIRUS; VERO CELL; VESICULAR STOMATITIS VIRUS; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELL LINE; COUMARINS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOME, VIRAL; HEPACIVIRUS; HUMANS; MOLECULAR STRUCTURE; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUSES;

HEPATITIS C VIRUS; TETRA;

EID: 38149026447     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.09.003     Document Type: Article

References (32)

1. Andrzejewska M., Yépez-Mulia L., Cedillo-Rivera R., Tapia A., Vilpo L., Vilpo J., and Kazimierczuk Z. Synthesis, antiprotozoal and anticancer activity of substituted 2-trifluoromethyl- and 2-pentafluoroethylbenzimidazoles. Eur. J. Med. Chem. 37 (2002) 973-978
2. Antonini I., Claudi F., Cristalli G., Franchetti P., Grifantini M., and Martelli S. Heterocyclic quinones with potential antitumor activity. 2. Synthesis and antitumor activity of some benzimidazole-4,7-dione derivatives. J. Med. Chem. 31 (1988) 260-264
3. Armstrong G.L., Alter M.J., McQuillan G.M., and Margolis H.S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 31 (2000) 777-782
4. Beaulieu P.L., and Llinàs-Brunet M. Therapies for hepatitis C infection: targeting the non-structural proteins of HCV. Curr. Med. Chem. Anti-Infect. Agents 1 (2002) 163-176
5. Beaulieu P.L., Bös M., Bousquet Y., DeRoy P., Fazal G., Gauthier J., Gillard J., Goulet S., McKercher G., Poupart M.-A., Valois S., and Kukolj G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorg. Med. Chem. Lett. 14 (2004) 967-971
6. Beaulieu P.L., Bousquet Y., Gauthier J., Gillard J., Marquis M., McKercher G., Pellerein C., Valois S., and Kukolj G. Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: Inhibition of subgenomic hepatitis C virus RNA replicons in huh-7 cells. J. Med. Chem. 47 (2004) 6884-6892
7. Bhan P., Bhan A., Hong M., Hartwell J.G., Saunders J.M., and Hoke G.D. 2′,5′-Linked oligo-3′-deoxyribonucleoside phosphorothioate chimeras: thermal stability and antisense inhibition of gene expression. Nucl. Acids Res. 25 (1997) 3310-3317
8. Bretner M. Existing and future therapeutic options for hepatitis C virus infection. Acta Biochim. Pol. 52 (2005) 57-70
9. Bretner M., Baier A., Kopanska K., Najda A., Schoof A., Reinholz M., Lipniacki A., Piasek A., Kulikowsi T., and Borowski P. Synthesis and biological activity of 1H-benzotriazole and 1H-benzimidazole analogues-inhibitors of the NTPase/helicase of HCV and of some related Flaviviridae. Antivir. Chem. Chemother. 16 (2005) 315-326
10. Coelmont L., Paeshuyse J., Windisch P., De Clercq M., Bartenschlager E., and Neyts R.J. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine. Antimicrob. Agents Chemother. 50 (2006) 3444-3446
11. Condron S.L., Heneghan M.A., Patel K., Dev A., McHutchison J.G., and Muir A.J. Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. Transplantation 80 (2005) 145-148
12. Curini M., Epifano F., Maltese F., Marcotullio M.C., Gonzales S.P., and Rodriguez J.C. Synthesis of collinin, an antiviral coumarin. Aust. J. Chem. 56 (2003) 59-60
13. Demirayak S., Mohsen U.A., and Karaburun A.C. Synthesis and anticancer and anti-HIV testing of some pyrazino[1 2-a]benzimidazole derivatives. Eur. J. Med. Chem. 37 (2002) 255-260
14. Devivar R.V., Kawashima E., Revankar G.R., Breitenbach J.M., Kreske E.D., Drach J.C., and Townsend L.B. Benzimidazole ribonucleosides: design, synthesis, and antiviral activity of certain 2-(alkylthio)- and 2-(benzylthio)-5 6-dichloro-1-(β-d-ribofuranosyl)benzimidazoles. J. Med. Chem. 37 (1994) 2942-2949
15. Duan D., Li Z., Luo H., Zhang W., Chen L., and Xu X. Antiviral compounds from traditional Chinese medicines Galla Chinese as inhibitors of HCV NS3 protease. Bioorg. Med. Chem. Lett. 14 (2004) 6041-6044
16. Garuti L., Roberti M., Malagoli M., Rossi T., and Castelli M. Synthesis and antiproliferative activity of some benzimidazole-4 7-dione derivatives. Bioorg. Med. Chem. Lett. 10 (2000) 2193-2195
17. 2] complexes. Eur. J. Med. Chem. 38 (2003) 473-480
18. Hirashima S., Suzuki T., Ishida T., Noji S., Yata S., Ando I., Komatsu M., Ikeda S., and Hashimoto H. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J. Med. Chem. 49 (2006) 4721-4736
19. Ishida T., Suzuki T., Hirashima S., Mizutani K., Yoshida A., Ando I., Ikeda S., Adachi T., and Hashimoto H. Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole. Bioorg. Med. Chem. Lett. 16 (2006) 1859-1863
20. Ito C., Itoigawa M., Mishina Y., Filho V.C., Enjo F., Tokuda H., Nishino H., and Furukawa H. Chemical constituents of Calophyllum brasiliense 2. Structure of three new coumarins and cancer chemopreventive activity of 4-substituted coumarins. J. Nat. Prod. 66 (2003) 368-371
21. Khodair A.I., Al-Masoudi N.A., and Gesson J.-P. A new approach to the synthesis of benzothiazole, benzoxazole, and pyridine nucleosides as potential. Antitumor Agents Nucleosides Nusleotides Nucl. Acids 22 (2003) 2061-2076
22. Klimesová V., Kocí J., Pour M., Stachel J., Waisser K., and Kaustová J. Synthesis and preliminary evaluation of benzimidazole derivatives as antimicrobial agents. Eur. J. Med. Chem. 37 (2002) 409-418
23. Lauer G.M., and Walker B.D. Hepatitis C virus infection. N. Engl. J. Med. 345 (2001) 41-52
24. Lohmann V., Korner F., Koch J., Herian U., and Theilmann L. Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line, Science 285 (1999) 110-113
25. Lukevics E., Arsenyan P., Shestakova I., Domracheva I., Nesterova A., and Pudova O. Synthesis and antitumour activity of trimethylsilylpropyl substituted benzimidazoles. Eur. J. Med. Chem. 36 (2001) 507-515
26. McKercher G., Beaulieu P.L., Lamarre D., LaPlante S., Lefebvre S., Pellerin C., Thauvette L., and Kukolj G. Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate. Nucl. Acids Res. 32 (2004) 422-431
27. Nam N.-H., Kim Y., You Y.-J., Hong D.-H., Kim H.-M., and Ahn B.-Z. Preliminary structure-antiangiogenic activity relationships of 4-senecioyloxymethyl-6 7-dimethoxycoumarin. Bioorg. Med. Chem. Lett. 12 (2002) 2345-2348
28. Neyts J. Selective inhibitors of hepatitis C virus replication. Antivir. Res. 71 (2006) 363-371
29. Paeshuyse J., Kaul A., De Clercq E., Rosenwirth B., Dumont J.M., Scalfaro P., Bartenschlager R., and Neyts J. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43 (2006) 761-770
30. Pawlotsky J.M., and Gish R.G. Future therapies for hepatitis C. Antivir. Ther. 11 (2006) 397-408
31. Penin F., Dubuisson J., Rey F.A., Moradpour D., and Pawlotsky J.-M. Structural biology of hepatitis C virus. Hepatology 39 (2004) 5-19
32. Zhang G., Shen J., Cheng H., Zhu L., Fang L., Luo S., Muller M.T., Lee G.E., Wei L., Du Y., Sun D., and Wang P.G. Syntheses and biological activities of rebeccamycin analogues with uncommon sugars. J. Med. Chem. 48 (2005) 2600-2611